Molinos Rio de la Plata SA (MOLI BA) stock market data APIs
ARS2808.4135
50.55(1.8%)
as of July 1, 2025
Try our APIs with
free plan!
Molinos Rio de la Plata SA Financial Data Overview
Price chart is built with
Anychart
Molinos Rio de la Plata S.A. engages in the industrialization and commercialization of food and alcoholic beverages in Argentina and internationally. It operates through Foods and Wineries segments. The company offers edible oils, pasta, dried, frozen, fractionated flour, grass, rice, wines, and sparkling wines. Molinos Rio de la Plata S.A. was incorporated in 1931 and is based in Buenos Aires, Argentina.
Prev. Close
2808.4135
Open
2858.9664
High
2994.6835
Low
2739.1076
52 wk Range
2710-6050
Market Cap
599 903 M
Shares Outstanding
201 M
Revenue
812 368 M
EPS
14.4039
Beta
0.041
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Molinos Rio de la Plata SA data using free add-ons & libraries
Get Molinos Rio de la Plata SA Fundamental Data
Molinos Rio de la Plata SA Fundamental data includes:
- Net Revenue: 812 368 M
- EBITDA: -45 343 997 952
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-05-10
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Molinos Rio de la Plata SA News
New
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation f...
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation f...
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Topline results from Phase 1/2 study on track for March 2021 Individual and cumulative data seen to-date show Trappsol® Cyclo™ to be well tolerated with a favorable safety profile for all dose gro...
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Topline results from Phase 1/2 study on track for March 2021 Individual and cumulative data seen to-date show Trappsol® Cyclo™ to be well tolerated with a favorable safety profile for all dose gro...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
